A biotech company said 400 people had been mistakenly informed they might have cancer.
Grail Inc said the error resulted from a software issue, which has been resolved.
The incident was part of a trial of an early-detection blood test called Galleri.
Grail Inc, an American biotechnology company, developed an early-detection blood test called Galleri, created to identify more than 50 types of cancer before symptoms appear, per Reuters.
The company, owned by gene sequencing company Illumina, said it promptly contacted patients after the incident.
Persons:
—, Grail, PWNHealth, MassMutual
Organizations:
Inc, Service, Financial Times, British
Locations:
American